Celsion to Present at the Lazard Capital Markets 9th Annual

Celsion to Present at the Lazard Capital Markets 9th Annual
Healthcare Conference 
LAWRENCEVILLE, NJ -- (Marketwire) -- 11/06/12 --  Celsion Corporation
(NASDAQ: CLSN), a leading oncology drug development company, today
announced that Michael H. Tardugno, Celsion's President and Chief
Executive Officer, will be presenting at the Lazard Capital Markets
9th Annual Healthcare Conference on Wednesday, November 14th at 2:00
PM Eastern Time in New York City. 
A live webcast of the presentation will be available on Celsion's
website at http://investor.celsion.com/events.cfm. The webcast will
be archived on the same site for replay following the conference. 
About Celsion 
Celsion is a leading oncology company dedicated to the development
and commercialization of innovative cancer drugs including
tumor-targeting treatments using focused heat energy in combination
with heat-activated liposomal drug technology. Celsion has research,
license, or commercialization agreements with leading institutions
including the National Institutes of Health, Duke University Medical
Center, University of Hong Kong, the University of Pisa, the UCLA
Department of Medicine, the Kyungpook National University Hospital,
the Beijing Cancer Hospital and the University of Oxford.  
For more information on Celsion, visit our website:
http://www.celsion.com. 
Celsion wishes to inform readers that forward-looking statements in
this release are made pursuant to the "safe harbor" provisions of the
Private Securities Litigation Reform Act of 1995. Readers are
cautioned that such forward-looking statements involve risks and
uncertainties including, without limitation, unforeseen changes in
the course of research and development activities and in clinical
trials by others; possible acquisitions of other technologies, assets
or businesses; possible actions by customers, suppliers, competitors,
regulatory authorities; and other risks detailed from time to time in
the Company's periodic reports filed with the Securities and Exchange
Commission.  
Investor Contact 
David Pitts 
Argot Partners 
212-600-1902 
David@argotpartners.com